In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eyenovia Inc.

www.eyenoviabio.com

Latest From Eyenovia Inc.

Eyenovia's Positive Phase III Data Support Its Topical Microdosing Platform

Company envisions pricing branded drug/device on par with the standard of care to speed adoption and lay the groundwork for a range of other indications.

Ophthalmic Research & Development

Deals Shaping The Medical Industry, February 2018

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2018.

Deals Medical Device

IPO Update: Seven In January As Big Returns, Solid's Slip-Up Contribute To Bubble Concerns

Seven biopharma IPOs launched in the US in January with an average return of 52.8%. The most recent was Sol-Gel's on Jan. 31, but the largest was a $128m offering by ARMO. Solid had the most controversial IPO, but it still gave investors a 70.7% return, contributing to the question: Is biotech in a bubble?

Financing Business Strategies

Deals Shaping the Medical Industry, January 2018

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2017.

Deals BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
    • OTC, Consumer
  • Therapeutic Areas
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Eyenovia Inc.
  • Senior Management
  • Sean Ianchulev, MD, Pres. & CEO
    John Gandolfo, CFO
    MIchael Rowe, VP, Mktg.
  • Contact Info
  • Eyenovia Inc.
    Phone: (917) 289-1117
    501 Fifth Ave., Ste. 1404
    New York, NY 10017
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register